Trials / Completed
CompletedNCT00645905
Study of Two Dosing Schedules of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 148 (actual)
- Sponsor
- Abbott · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Study of Two Dosing Schedules of Adalimumab in Subjects with Moderate to Severe Chronic Plaque Psoriasis
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | adalimumab | OL 80 mg at Week 0, 40 mg weekly through Week 12, blinded 40 mg eow through Week 48, withdrawal and observation for 360 days after last dose |
| DRUG | placebo for adalimumab | OL 80 mg at Week 0, 40 mg weekly through Week 12, blinded placebo eow through Week 48, withdrawal and observation for 360 days after last dose |
Timeline
- Start date
- 2003-06-01
- Primary completion
- 2005-03-01
- First posted
- 2008-03-28
- Last updated
- 2008-03-28
Source: ClinicalTrials.gov record NCT00645905. Inclusion in this directory is not an endorsement.